The Primary Peritoneal Cancer Therapeutics Market report by Persistence Market Research focuses on the healthcare trends to be pondered about in the upcoming period. When the world at large is gripped with predictive analysis and data science, the healthcare industry cannot remain untouched. These two advancements ascertain that the doctors could monitor, access, or even intervene in real-time reports of the patients.
Peritoneal cancer is a rate type of malignant tumour of the peritoneum, a layer of tissue that lines the abdomen. Peritoneal cancer develops from metastases of other tumours, mostly from gastric, intestinal, and ovarian cancers. According to Robert Koch Institute’s Centre for Cancer Registry, there were around 15,600 people diagnosed with stomach cancer, 7,300 women with ovarian cancer, and 62,400 individuals with colorectal cancer in 2013. Out of the total diagnosed population, 15-20% cases have led to peritoneal metastases.
Patients suffering from gastric cancer have a higher chance (30%) of developing peritoneal cancer at some point in their disease. The survival rate of peritoneal cancer, if left untreated, is around 3-6 months. Peritoneal cancer is sometimes left untreated, as it cannot be detected by radiological imaging. This is the main reason for lower reported incidences of peritoneal cancer, and hence, it is considered as a very rare form of cancer.
The growing number of reported incidences of peritoneal cancer due to increased awareness is anticipated to boost the growth of the primary peritoneal cancer therapeutics market. The increasing number of patients suffering from metastatic gastric, intestinal, and ovarian cancers is expected to increase the incidences of peritoneal cancer, which would lead to an increase in the demand for primary peritoneal cancer therapeutics.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/24115
The growing demand for a multidisciplinary treatment regime in closed care and increased spending on palliative care for patient in the end stage of disease are likely boost the growth of the primary peritoneal cancer therapeutics market. However, limitation in terms of targeted therapy and lack of effective diagnostic technologies are expected to hamper the growth of the primary peritoneal cancer therapeutics market.
Market Segmentation:
| Based on treatment type |
|
| Based on end user |
|
Over the last two decades, the treatment regime for peritoneal cancer has changed drastically. Many hospitals are offering closed care with specific expertise in peritoneal cancer. Multidisciplinary teams of experts who assess patients during treatment includes medical oncologists, oncologists with expertise in peritoneal cancer, pathologists, and dedicated radiologists. However, optimal treatment is still dependent on many other factors such as age, general condition, and severity of the peritoneal cancer. There are two treatment options available for peritoneal cancer patients, which includes treatment with palliative intent and treatment with curative intent.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/24115
The first options involves treatment with palliative intent to reduce the pain, surgical intervention to resolve bowel obstruction, and treatment with systemic chemotherapy. The second method of treatment with curative intent involves multidisciplinary action on peritoneal cancer with systemic chemotherapy, hyperthermic intraperitoneal chemotherapy, and tumor removal surgery. Chemotherapy with additional hormonal therapy (anastrozole, letrozole) is used to treat advanced types of peritoneal cancer. The targeted therapy segment along with chemotherapy are expected to boost the growth of the primary peritoneal cancer therapeutics market.
Geographically, the global primary peritoneal cancer therapeutics market is segmented into regions, viz. North America, Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa. Closed care treatment planning with a multidisciplinary approach from hospitals is expected to boost the growth of the primary peritoneal cancer therapeutics market. The growing number of patients suffering from metastatic gynecology and gastrointestinal cancer is expected to increase the incidence rate of peritoneal cancer. This growth is expected to result in the increased demand for primary peritoneal cancer therapeutics in Asia.
Some of the players identified in the global primary peritoneal cancer therapeutics market include Novartis Pharmaceuticals Corporation, Genentech USA, Astra Zeneca, Sanofi Aventis, and Pfizer, among others.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/24115
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com